lutetium LU 177-edotreotide

{
  "id": "MLC-T-ONC-014935",
  "term": "lutetium LU 177-edotreotide",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).",
  "abbreviation": "[177LuDOTA]-TOC",
  "synonyms": [
    "177Lu-DOTA-Tyr3-octreotide",
    "lutetium Lu 177-DOTA-edotreotide",
    "lutetium Lu 177 DOTA-tyr3-octreotide"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-edotreotide/"
}